Q2 Earnings Estimate for BEAM Issued By Leerink Partnrs

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Beam Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.28) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.30) EPS and FY2025 earnings at ($5.11) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.16. The business had revenue of $30.00 million for the quarter, compared to analyst estimates of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm’s quarterly revenue was down 90.5% on a year-over-year basis. During the same period last year, the business posted $1.73 earnings per share.

A number of other analysts have also commented on BEAM. Wedbush reissued an “outperform” rating and issued a $57.00 price objective on shares of Beam Therapeutics in a research report on Monday, January 13th. Leerink Partners raised shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $27.00 to $39.00 in a research report on Wednesday, November 6th. Royal Bank of Canada raised their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the company a “sector perform” rating in a report on Wednesday. Sanford C. Bernstein upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 7th. Finally, Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $50.90.

Beam Therapeutics Price Performance

Shares of Beam Therapeutics stock opened at $27.11 on Friday. Beam Therapeutics has a one year low of $20.84 and a one year high of $45.79. The stock’s 50-day moving average is $27.23 and its 200-day moving average is $25.92. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -15.40 and a beta of 1.92.

Institutional Investors Weigh In On Beam Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Beam Therapeutics by 59.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company’s stock valued at $87,044,000 after buying an additional 1,328,414 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Beam Therapeutics by 8.2% in the 4th quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company’s stock valued at $175,287,000 after purchasing an additional 536,930 shares in the last quarter. Casdin Capital LLC increased its stake in shares of Beam Therapeutics by 61.3% in the 4th quarter. Casdin Capital LLC now owns 1,250,000 shares of the company’s stock valued at $31,000,000 after purchasing an additional 475,000 shares during the last quarter. State Street Corp raised its holdings in shares of Beam Therapeutics by 12.5% during the 3rd quarter. State Street Corp now owns 3,929,557 shares of the company’s stock worth $96,274,000 after buying an additional 437,402 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its position in shares of Beam Therapeutics by 11.4% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company’s stock worth $98,109,000 after buying an additional 404,782 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 1,241 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total transaction of $30,627.88. Following the transaction, the insider now owns 102,968 shares in the company, valued at $2,541,250.24. This represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total transaction of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.